Key Highlights

  • BrightSpring Health Services traded at US$63.80, against a consensus target of US$71.53.
  • The median target of US$78 implies roughly +22.3% upside from the current price.
  • Targets span US$41 to US$90, framing the range of analyst opinion.
  • The consensus implies +12.1% upside, reflecting the balance of current analyst views.

BrightSpring Health Services (NASDAQ:BTSG) traded at US$63.80 as of 8 October 2026, against an analyst consensus price target of US$71.53, an implied upside of approximately +12.1%.

What Is the Latest Analyst Price Target?

The data provider screener as at 8 October 2026 shows a mean analyst price target of $71.53 and a median of $78. The lowest target is $41 and the highest is $90. Measured from the $63.80 close, the mean implies potential upside of 12.1%, while the median suggests a bigger gap. The trailing price-to-earnings ratio is 38.4, and no Dividend is paid.

What Are Analysts Saying?

The provider's consensus rating is Strong buy. The $41 low sits about 36% below the current price, whereas the $90 high is roughly 41% above it. The median of $78 is some $6.50 higher than the $71.53 mean, which suggests a few low estimates are pulling the average down. Most forecasts may therefore be clustered closer to the upper end than the mean implies. The width of the range, with $49 separating the low from the high, points to disagreement over how quickly margins can improve and how exposed the Business is to policy shifts. Even so, the price sits below the mean, median and every target except the lowest, which may leave room for sentiment to improve if results are strong.

What Could Help the Stock Reach the Price Target?

The company has positioned itself across pharmacy services and provider services, supporting complex-needs patients, older adults and people with disabilities outside hospitals. If analysts prove correct, ageing populations, policy preference for lower-cost settings of care, and growth in specialty and infusion pharmacy could support revenue. Acquisitions of smaller operators and Operating Leverage as volumes rise may also help profitability. Demand for care at home has been broadly supported by patient preference as well as cost pressure on hospitals, which gives the sector a structural tailwind that is relatively independent of the economic cycle.

What Could Prevent the Stock Reaching the Target?

The business relies heavily on government payers such as Medicare and Medicaid, so changes to reimbursement rates or eligibility could affect earnings. Labour is a major cost, and shortages or wage Inflation among caregivers can squeeze margins. The company carries Debt from its buyout history, and regulatory investigations or compliance issues are a recognised risk in healthcare services. With the $41 low target well below the price, downside scenarios are visible. Tighter scrutiny of drug pricing and pharmacy reimbursement could also affect the pharmacy division.

What Should Investors Watch Next?

The next quarterly results and guidance will show organic growth, Margin trends and progress reducing leverage. Investors may follow decisions on reimbursement rates, any acquisitions, and how the pharmacy and provider segments are performing relative to each other. Commentary on staffing costs and on policy developments in federal and state health programmes will also be closely read. Investors may also follow the company's progress on integrating acquisitions and any further reduction in debt, because both would influence how the market values the shares.

Why the Numbers on BrightSpring Health Services Diverge

BrightSpring Health Services (BTSG) was priced at US$63.80 against a consensus target of US$71.53, an implied upside of approximately +12.1%. The median target of US$78 and the range of US$41 to US$90 frame the debate among analysts.